Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 15/20 | 1.00 |
| ▸ | PLG | P00747 | 6/20 | 1.00 |
| ▸ | KLK1 | P06870 | 5/20 | 1.00 |
| ▸ | F2 | P00734 | 5/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 4/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 3/20 | 1.00 |
| ▸ | F12 | P00748 | 2/20 | 0.67 |
| ▸ | PLAT | P00750 | 4/20 | 0.62 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.62 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941688 | 1.00 | PLAU (1.00) | PLAUPLGKLK1F2PRSS1 | |
| SCHEMBL8169767 | 0.85 | PLAU (0.72) | PLAUPLGKLK1F2PRSS1 | |
| SCHEMBL7342926 | 0.82 | PLAU (0.74) | PLAUPLGKLK1F2PRSS1 | |
| SCHEMBL16321764 | 0.80 | PRSS1 (0.65) | PLAUPLGKLK1F2PRSS1 | |
| SCHEMBL7335930 | 0.80 | PLAU (0.78) | PLAUPLGKLK1F2PRSS1 | |
| SCHEMBL31499215 | 0.80 | F12 (1.00) | PLAUPLGKLK1F2PRSS1 | |
| SCHEMBL29568530 | 0.80 | F12 (1.00) | PLAUPLGKLK1F2PRSS1 | |
| SCHEMBL3301671 | 0.80 | F12 (1.00) | PLAUPLGKLK1F2PRSS1 | |
| SCHEMBL7362642 | 0.80 | PLAU (0.72) | PLAUPLGKLK1F2PRSS1 | |
| SCHEMBL10492936 | 0.79 | PRSS1 (0.64) | PLAUPLGKLK1F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905262-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-02-20 | — | — | US | claimed |
| EP-1276722-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | claimed |
| WO-2001081314-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | claimed |
| US-20240150506-A1 | CURING AGENTS FOR FLUOROELASTOMERS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2024-05-09 | — | — | US | disclosed |
| US-11958815-B1 | N′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as antimicrobial compound | King Faisal University (SA) | 2024-04-16 | — | — | US | disclosed |
| US-11905262-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-02-20 | — | — | US | disclosed |
| EP-4305096-A1 | FLUOROELASTOMERS COMPOSITION COMPRISING CURING AGENTS | Dupont Specialty Products USA, LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023148783-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-08-10 | — | — | WO | disclosed |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11679093-B2 | 2-naphthimidamides, analogues thereof, and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679093-B2 | 2-naphthimidamides, analogues thereof, and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-06-20 | — | — | US | disclosed |
| CN-85107531-A | Process for producing vinyl chloride polymer | — | 1987-01-21 | — | — | CN | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
| US-4259482-A | NON-SPECIFIC DEPRESSION OF CENTRAL NERVOUS SYSTEM | MEAD JOHNSON & COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4206142-A | REACTING A STYRYLSULFONYLAMIDINE WITH A BASE | MEAD JOHNSON & COMPANY (US) | 1980-06-03 | — | — | US | disclosed |
| US-4169772-A | REACTION PRODUCT OF FORMALDEHYDE, A NITROGENHETEROCYCLIC COMPOUND AND AN EPIHALOHYDRIN OR A GLYCEROL HALOHYDRIN AS LEVELING AGENT | R. O. HULL & COMPANY, INC. (US) | 1979-10-02 | — | — | US | disclosed |
| US-4134992-A | NAPHTHALENE ACETAMIDINES AS ANXIOLYTIC ANTIDEPRESSANTS | THE DOW CHEMICAL COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
| US-4130663-A | ANTITHROMBOGENIC, ANTIHYPERTENSIVE | MEAD JOHNSON & COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
| US-4096183-A | Styrylsulfonylamidines | MEAD JOHNSON & COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4052455-A | ANALGESICS, BLOOD PLATELET AGGREGATION INHIBITORS | MEAD JOHNSON & COMPANY (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905262-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound | NIT2, NOC2L, B3GNT2 | PLAU 3923/4885PLG 4356/4885KLK1 2051/4885 |
| US-11958815-B1 | N′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as antimicrobial compound | NIT2, NOC2L, NANP | PLAU 3535/4885PLG 3041/4885KLK1 2122/4885 |
| US-11679093-B2 | 2-naphthimidamides, analogues thereof, and methods of treatment using same | TMPRSS2, TMPRSS4, TMPRSS15 | PLAU 654/4885PLG 546/4885KLK1 1031/4885 |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | PLAU 1328/4885PLG 1740/4885KLK1 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.